To date this year, not a single innovative drug-focused biotech has filed for an initial public offering on the Science and Technology Innovation Board of the Shanghai Stock Exchange. Apart from a suspected tightening of listing rules, IPO disclosures and the plummeting share prices of public companies seem to be looming large over bioventures aiming considering floating on the bourse.

Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

Deal Snapshot: Teaming again with the Shanghai biotech, AstraZeneca will seek assays that can be incorporated into companion diagnostics for Lynparza in prostate and breast cancer.

Focused on the Chinese Market, the Shanghai-based bioventure is pushing ahead with a differentiated clinical development strategy for its top in-licensed asset Trodelvy, as an uphill fight looms over the antibody-drug conjugate therapy outside of China, the company’s president says in an interview.